Search

Background: Several studies have shown that both acupuncture and dry needling are effective in the treatment of musculoskeletal pains. Therefore, the aim of this network meta‐analysis (NMA) was to investigate the treatment outcome of acupuncture and dry‐needling for masticatory muscle pain (TMD‐M) and to compare with active and inactive placebo. Material and Method: An electronic search was performed to identify randomised controlled trials (RCTs) published until September 2019, comparing dry‐needling, acupuncture, and inactive as well as active placebo in patients with TMD‐M. Outcome variables were post‐treatment pain intensity, pressure pain threshold (PPT), and maximum mouth opening (MMO). The quality of evidence was rated according to Cochrane's tool for assessing the risk of bias. Mean difference was used to analyse via frequentist NMA using STATA‐software. Results: Both NMA and direct pairwise meta‐analysis have shown that there was no difference between active treatment with either acupuncture or dry‐needling when compared to active and inactive placebo in patients with TMD‐M with respect to pain intensity, and PPT (p >.05). However, there was a significant increase in MMO following dry‐needling when compared to the placebo (very low‐quality evidence). Conclusion: Despite the short‐term positive effect of MMO by dry‐needling, this NMA could not show any pain‐reducing effect in patients with TMD‐M by acupuncture or dry‐needling when compared to an active or inactive placebo. Taken together, this NMA indicates that it is the placebo effect that accounts for the majority of the treatment effect of TMD‐M, rather than a real therapeutic effect of acupuncture/dry‐needling. [ABSTRACT FROM AUTHOR]

Objective: A network meta‐analysis (NMA) of randomised clinical trials (RCTs) was performed aiming to compare the treatment outcome of dry needling, acupuncture or wet needling using different substances in managing myofascial pain of the masticatory muscles (TMD‐M). Method: An electronic search was undertaken to identify RCTs published until September 2019, comparing dry needling, acupuncture or wet needling using local anaesthesia (LA), botulinum toxin‐A (BTX‐A), granisetron, platelet‐rich plasma (PRP) or passive placebo versus real active placebo in patients with TMD‐M. RCTs meeting the inclusion criteria were stratified according to the follow‐up time: immediate post‐treatment to 3 weeks, and 1 to 6 months post‐treatment. Outcome variables were post‐treatment pain intensity, increased mouth opening (MMO) and pressure threshold pain (PPT). The quality of evidence was rated according to Cochrane's tool for assessing risk of bias. Mean difference (MD) was used to analysed via frequentist NMA using Stata software. Results: Twenty‐one RCTs involving 959 patients were included. The quality of evidence of the included studies was low or very low. There was significant pain decrease after PRP when compared to an active/passive placebo and acupuncture. There was a significant improvement of MMO after LA (MD = 3.65; CI: 1.18‐6.1) and dry needling therapy (MD = 2.37; CI: 0.66‐4) versus placebo. The three highest ranked treatments for short‐term post‐treatment pain reduction in TMD‐M (1‐20 days) were PRP (95.8%), followed by LA (62.5%) and dry needling (57.1%), whereas the three highest ranked treatments at intermediate‐term follow‐up (1‐6 months) were LA (90.2%), dry needling (66.1%) and BTX‐A (52.1%) (all very low‐quality evidence). LA (96.4%) was the most effective treatment regarding the increase in MMO followed by dry needling (72.4%). Conclusion: Based on this NMA, one can conclude that the effectiveness of needling therapy did not depend on needling type (dry or wet) or needling substance. The outcome of this NMA suggests that LA, BTX‐A, granisetron and PRP hold some promise as injection therapies, but no definite conclusions can be drawn due to the low quality of evidence of the included studies. This NMA did not provide enough support for any of the needling therapies for TMD‐M. [ABSTRACT FROM AUTHOR]

Aims: To evaluate the effectiveness of acupuncture in treating symptoms associated with myofascial pain of the jaw muscles. Methods: Twenty-eight subjects over the age of 18 and diagnosed with chronic myofascial pain of the jaw muscles were randomized to receive real (n = 16) or sham (n = 12) acupuncture. Prior to treatment, each subject clenched his or her teeth for 2 minutes. Acupuncture or sham acupuncture was then administered at the Hegu large intestine 4 (LI4) acupoint for 15 minutes. Real acupuncture was given by penetrating the needle through a sticky foam pad at the acupoint. Sham acupuncture was conducted by pricking the skin, without penetration, with a shortened, blunted acupuncture needle through a foam pad placed away from the acupoint. General head and neck pain ratings were obtained before and after treatment on a numerical rating scale. A mechanical pain stimulus on the masseter muscle was given before and after treatment and rated on a visual analog scale to measure pain tolerance level. Paired t tests were performed to detect significant changes in pain levels. Results: Subjects receiving real acupuncture experienced a significant reduction in jaw pain (P = .04), jaw/face tightness (P = .04), and neck pain (P = .04), and a significant increase in pain tolerance of the masseter muscle (P = .001). Subjects were not able to determine whether they received real or sham acupuncture (P = .69). No significant pain reductions were observed in the sham acupuncture group. Conclusion: A single acupuncture session using one acupoint at Hegu large intestine 4 significantly reduced most myofascial pain endpoints when compared to sham acupuncture. [ABSTRACT FROM AUTHOR]

This article presents a comprehensive review of the topic of placebos, with a special focus on placebo analgesia. It includes a discussion of how placebos work (the placebo effect) and how patients react to them (the placebo response). A literature search was performed to identify relevant literature and publications related to the topic, and a qualitative assessment of papers was undertaken based on accepted rules for scientific evidence. The major finding from this review was that concepts about placebo effects and responses have changed dramatically over the years, especially in more recent years. This has occurred primarily as a result of more sophisticated experimental protocols using placebos in clinical studies of patients in pain, as well as various studies involving normal subjects. Our understanding of the biological and psychological mechanisms underlying placebo effects has expanded significantly due to recent developments in the technology of brain imaging. Based on findings from brain-imaging analyses, we now know that placebo analgesia is definitely a real (ie, biologically measurable) phenomenon. It can be pharmacologically blocked and behaviorally enhanced, and these responses have been demonstrated to be similar to those elicited by administration of "real" analgesic substances. Psychological mechanisms involved in placebo analgesia include expectancy, meaning response, and classical conditioning. This article concludes with an emphasis on understanding therapeutic responses to various treatments for temporomandibular disorders (TMD). Acupuncture and splint therapy can be good examples of powerful placebos in the field of TMD, and both of these are discussed in detail. Present knowledge suggests that every treatment for pain contains a placebo component, which sometimes is as powerful as the so-called "active" counterpart. While the deceptive use of placebos must be considered unethical, every health provider who is treating pain patients must be aware of this important phenomenon in order to harness its huge potential. [ABSTRACT FROM AUTHOR]

Aims: To compare the effectiveness of dry needling in classically recognized acupuncture points ("acupuncture") with dry needling in skin areas not recognized as acupuncture points ("sham acupuncture") in reducing masseter muscle pain in a group of patients with myofascial pain of the jaw muscles. Methods: Eighteen patients were randomly assigned to 1 of 2 experimental groups: Ten patients received acupuncture and 8 received sham acupuncture. A visual analog scale (VAS) was used to measure changes in masseter muscle pain evoked by mechanical stimulation of the masseter muscle before and after the experiment. Results: Both groups showed a statistically significant reduction in VAS pain scores (P = .001). Seven out of 10 acupuncture subjects had a 10 mm or greater VAS reduction in pain, while 4 out of 8 of the sham acupuncture subjects had that great a pain reduction. There was no significant difference between the 2 groups. Conclusion: Both acupuncture and sham acupuncture reduced pain evoked by mechanical stimulation of the masseter muscles in myofascial pain patients. However, this reduction in pain was not dependent on whether the needling was performed in standard acupuncture points or in other areas of the skin. These results suggest that pain reduction resulting from a noxious stimulus (ie, needling) may not be specific to the location of the stimulus as predicted by the classical acupuncture literature. [ABSTRACT FROM AUTHOR]

Summary: A reliable assessment method is required to manage the gag reflex. We tested the inter‐ and intra‐examiner reliability and validity of a quantitative measurement method and evaluated the differences between sexes. This study included 21 healthy adults (10 women, 11 men; mean age, 27.1 ± 9.9 years). An examiner inserted a standard saliva ejector slowly down the participant's throat to determine the maximum tolerance of the gag reflex; the insertion depth was used as an index of gag reflex. The reflex was measured by one examiner during two sessions (S1 and S3) and by a second examiner during one session (S2) under the same conditions. The galvanic skin response (GSR) and heart rate (HR) were recorded during each session to test the method validity. Data were analysed using the intraclass correlation coefficient (ICC), paired t test, and two‐way repeated‐measures analysis of variance. The ICC of the gag reflex measurements was 0.91 between S1 and S2, and 0.93 between S1 and S3. The GSR and HR increased significantly after the maximum tolerance of the reflex in S1, S2, and S3 (GSR: P < 0.001, P = 0.004, P = 0.001, respectively; HR: all, P < 0.001). Differences in the measurements according to sex and session were not significant. Our method exhibited excellent inter‐ and intra‐examiner reliability and was unaffected by the participants’ sex. Measurement revealed significant autonomic reactivity, which is common for this reflex. Consequently, this method may be used in clinical and laboratory‐based applications. [ABSTRACT FROM AUTHOR]

Aims: To carry out a systematic review to assess the effectiveness of cannabis extracts and cannabinoids in the management of chronic nonmalignant neuropathic pain. Methods: Electronic database searches were performed using Medline, PubMed, Embase, all evidence-based medicine reviews, and Web of Science, through communication with the Canadian Consortium for the Investigation of Cannabinoids (CCIC), and by searching printed indices from 1950. Terms used were marijuana, marihuana, cannabis, cannabinoids, nabilone, delta- 9-tetrahydrocannabinol, cannabidiol, ajulemic acid, dronabinol, pain, chronic, disease, and neuropathic. Randomized placebo-controlled trials (RCTs) involving cannabis and cannabinoids for the treatment of chronic nonmalignant pain were selected. Outcomes considered were reduction in pain intensity and adverse events. Results: Of the 24 studies that examined chronic neuropathic pain, 11 studies were excluded. The 13 included studies were rated using the Jadad Scale to measure bias in pain research. Evaluation of these studies suggested that cannabinoids may provide effective analgesia in chronic neuropathic pain conditions that are refractory to other treatments. Conclusion: Cannabis-based medicinal extracts used in different populations of chronic nonmalignant neuropathic pain patients may provide effective analgesia in conditions that are refractory to other treatments. Further high-quality studies are needed to assess the impact of the duration of the treatment as well as the best form of drug delivery. [ABSTRACT FROM AUTHOR]

Background: Subjective symptoms of temporomandibular disorders (TMDs) have rarely been studied by age group. We aimed to compare self-reported pain intensity, sleeping difficulty, and treatment outcomes of patients with myofascial TMDs among three age groups. Methods: The study population included 179 consecutive patients (151 women and 28 men) who underwent comprehensive clinical examinations at a university-based orofacial pain center. They were classified into myofascial pain subgroups based on the Research Diagnostic Criteria for Temporomandibular Disorders. They were stratified by age group: M1, under 20 years; M2, 20-39 years; and M3, 40 years and older. The patients scored their pretreatment symptoms (first visit) and post-treatment symptoms (last visit) on a form composed of three items that assessed pain intensity and one item that assessed sleeping difficulty. Their treatment options (i.e., pharmacotherapy, physical therapy, and orthopedic appliances) and duration were recorded. All variables were compared between sexes in each group and between the age groups by using the Kruskal-Wallis test, the Mann-Whitney U test, the chisquare test, and analysis of variance (p < 0.05). Results: No significant sex differences were found in any age group. Only sleeping difficulty was significantly different before treatment (p = 0.009). No significant differences were observed in the treatment options or treatment duration. After treatment, the intensity of jaw/face pain and headache and sleeping difficulty was significantly reduced in groups M2 and M3, but only the intensity of jaw/face pain was significantly decreased in group M1. The changes in the scores of pain intensity and sleeping difficulty were not different between the groups. Conclusions: Pain intensity does not differ by age group, but older patients with myofascial TMDs had greater sleeping difficulties. However, there were no differences between the age groups in the treatment outcomes. Clinicians should carefully consider the age-related characteristics of patients with myofascial TMDs when developing appropriate management strategies. [ABSTRACT FROM AUTHOR]

Objectives: Headaches are a common complaint in temporomandibular disorder (TMD) patients. However, few studies have compared the symptom characteristics between TMD patients with and without a complaint of headache. The aim of this study was to compare subjective symptoms and treatment outcomes between myofascial TMD patients who had a chief complaint of headache and those who did not. Methods: One hundred sixty one patients underwent comprehensive examinations and scored their pre- and post-treatment symptoms on a form (4 items assessing pain intensity and 1 assessing sleeping difficulty). On the basis of the primary diagnosis, patients were divided into two groups: myofascial pain with and without a chief complaint of headache (MPH and MP). Results: Before treatment, patients in the MPH group scored significantly higher with respect to pain intensity and level of sleeping difficulty than did patients in the MP group (jaw/face pain, P = 0.015; headache, P < 0.001; neck pain, P < 0.001, and difficulty in sleeping, P = 0.005; Mann-Whitney U-test). Patients in the two groups demonstrated similar treatment outcomes, except for neck pain. Conclusion: Significant differences in symptom characteristics and outcomes were observed between primarily myofascial TMD patients with and without a chief complaint of headache. [ABSTRACT FROM AUTHOR]

The authors assessed the subjective symptoms of temporomandibular disorders (TMDs) in 167 young patients using self-reported forms, with five ratings for pain intensity and six ratings for difficulty in activities of daily living (ADL), to compare TMD symptoms according to gender and three age groups: group 1: 6- to 12-year-olds (juvenile); group 2: 13- to 15-year-olds (early adolescent); group 3: 16- to 18-year-olds (late adolescent). No significant gender differences were found in the symptoms among the groups, except for headache and neck pain in group 3. Pain intensity and tightness in the jaw/face, headache, and neck pain, as well as the ADL-related difficulty in prolonged jaw opening, eating soft/hard foods, and sleeping significantly differed among the groups (p<0.01, Kruskal-Wallis test). Therefore, late adolescent patients with TMDs have higher pain intensity in the orofacial region and greater difficulty in ADL than do early adolescent and juvenile patients with TMDs. [ABSTRACT FROM AUTHOR]

The authors compared the pain intensity and difficulty experienced in performing activities of daily living (ADL) among 237 patients with orofacial pain. The patients underwent comprehensive examinations and recorded their subjective symptoms on a form (five items for pain intensity and six for ADL-related difficulty). On the basis of the primary diagnosis, the patients were divided into the temporomandibular joint dysfunction (TMJ), myofascial pain (MP), neuropathic pain (NP), and fibromyalgia (FM) groups. The intensity of pain in the jaw/face, tightness in the jaw/face, pain in the neck, and toothache significantly differed among the groups (p<0.01, Kruskal-Wallis test). Compared to other patients, the FM and NP groups reported greater pain intensity, whereas those in the TMJ group reported lesser pain intensity. The ADL-related difficulty was not significantly different among the groups. Thus, compared to pain due to joint-related disorders, myalgic and neuropathic pain seem to be of higher intensity. [ABSTRACT FROM AUTHOR]

According to Centers for Disease Control and Prevention (CDC) estimates, there have been almost 930,000 AIDS cases diagnosed at the end of 2003 in the United States. About 3,000 of those infected were American Indian and Alaska Natives (AI/ANs). Persons with MV and AIDS have been shown to have increased risk of dental and periodontal disease. Unfortunately, there are no publications on dental disease and Al/ANs with HIV/AIDS. This study addresses this shortcoming by examining the relationship between dental health, drug use, and HIV among Al/AN patients in an urban setting. The study included a consecutive chart review of 51 Al/AN HIV-positive dental patients seen from 2001 to 2004 at the Native American Health Center in San Francisco. Results showed that 55% had moderate or severe periodontal disease, 80.4% had tooth decay, and 88.2% had missing teeth. Substance users had more dental caries or decayed teeth than non-substance users (88% versus 73%). The average rate for decayed, missing or filled teeth (DMFT) among the total sample was 18.73%. This chart review study suggests that dental disease is more prevalent in AI/ANs with HIV/ AIDS when compared to the general population and Al/AN data from the Indian Health Service. [ABSTRACT FROM AUTHOR]